StopDown
Acquisition · 22 June 2026TredenceData analytics and AI company

Tredence acquires US pharma analytics firm KMK Consulting

By · Editor ·

BengaluruFounded 2013
  • Tredence helps large businesses use data and build AI-powered software
  • It acquired KMK Consulting, a US-based pharma and life sciences analytics firm, for an undisclosed sum
  • Healthcare and life sciences are expected to be 25% of Tredence revenue by 2028

What happened

  • Tredence, a data analytics company based in Bengaluru and San Jose, has acquired KMK Consulting.
  • KMK Consulting is a US-based firm founded in 2000 that specialises in pharma and life sciences analytics.
  • The financial terms of the acquisition were not disclosed.
  • KMK works with 8 of the world's top 10 pharma companies.
  • KMK's expertise includes commercial analytics, patient analytics, market access, real-world evidence, and market research.
  • Tredence contributes AI engineering, data platforms, and enterprise-scale deployment to the combined offering.
  • Tredence expects healthcare and life sciences to make up 25% of its revenue by 2028.

Why it matters

  • The pharma industry spends about $250 billion annually on R&D and a similar amount on commercialisation.
  • Analytics and AI services for life sciences are growing at a CAGR of 20% to 25%.
  • Tredence is targeting $1 billion in revenue by 2030 through organic growth and acquisitions.
  • Future acquisition focus areas include communications, media, and insurance.

The business

  • Tredence helps large businesses use data and builds AI-powered software for customer behaviour, operations, and sales.
  • Its AI stack includes the decision intelligence platform Atom.AI, the ML platform ML Works, and agentic AI.
  • Tredence's annual revenue for calendar year 2026 is roughly $250 million.
  • The company is on track to grow about 45% this year.
  • KMK Consulting specialises in commercial analytics, patient analytics, market access, real-world evidence, and market research.
  • KMK works with 8 of the world's top 10 pharma companies.

The founders

Shub Bhowmick

cofounder
  • Co-founded Tredence in 2013.

Sumit Mehra

cofounder
  • Co-founded Tredence in 2013.

Shashank Dubey

cofounder and chief revenue officer
  • Co-founded Tredence in 2013.
  • Serves as chief revenue officer.

In numbers

$250 millionAnnual revenue (CY26) · 2026
45%Revenue growth rate · 2026
$1 billionRevenue target · 2030
25%Healthcare revenue share target · 2028

What happens next

  • Tredence is targeting $1 billion in revenue by 2030 through organic growth and acquisitions.
  • The company may explore a fresh fundraise in calendar year 2027.
  • Tredence may evaluate an IPO in the future, but listing is 'an option, not a compulsion'.
  • Future acquisition focus areas include communications, media, and insurance.

Words to know

CAGR
Compound annual growth rate – the average yearly growth rate of an investment or business over a period of time.
Real-world evidence
Data on patient health and treatment outcomes collected outside of clinical trials, from sources like electronic health records and insurance claims.
Agentic AI
Artificial intelligence systems that can act autonomously to achieve goals, make decisions, and perform tasks without constant human guidance.

The numbers around it

Enterprise Software & IT in June 2026: 12 rounds with a disclosed amount, $67.7 million in all; the biggest was JustAI ($17M). Every sector this year →

Read it as a card in the app

Terms in this story

  • Mergers and acquisitions: An acquisition is when one company buys another, and a merger is when two companies combine into one. For most Indian startups a sale is a likelier exit than an IPO, and the Competition Commission of India (CCI) must approve deals that cross its asset, turnover or ₹2,000 crore deal-value limits.

Everything on Tredence → · All startup news on 22 June 2026 →

Is this Tredence? Get your “Featured on StopDown” badge →